Head & Neck Cancers | Specialty

Evidence Builds for Electric Field Therapy in Recurrent GBM

August 19th 2014

A wearable device that uses electric fields to disrupt the activity of cancer cells has demonstrated survival benefits among patients with recurrent glioblastoma multiforme in real-world settings, particularly among individuals treated in earlier stages of progression

Transoral Surgery for Oropharyngeal Squamous Cell Carcinoma

August 11th 2014

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.

Study Finds Mouth Rinse Alleviates Oral Mucositis Symptoms in Head and Neck Cancers

July 28th 2014

A growing understanding of the biological pathways at work in the development of oral mucositis in patients treated with cytotoxic cancer therapies has helped spur interest in steering symptom management away from "institutional folklore" rinses and anecdotal approaches toward evidence-based strategies

Dr. Cmelak Discusses the Results of the ECOG1308 Study

July 24th 2014

Anthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.

Utilization of Cetuximab in Head and Neck Cancer

July 16th 2014

Oncology Nurse's Role in Side Effect Management for HNC

July 16th 2014

Cetuximab Safety Profile in Head and Neck Cancer

July 16th 2014

Cetuximab in Advanced HPV-Positive HNC

July 16th 2014

Treatments for HPV-Negative Head and Neck Cancer

July 16th 2014

Diagnosis and Treatment of HPV-Positive HNC

July 16th 2014

Evolving Head and Neck Cancer Treatment Landscape

July 16th 2014

Dr. Wirth Discusses the Safety Profile of Lenvatinib as Seen in the SELECT Trial

July 15th 2014

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the safety profile of lenvatinib as seen in the phase III SELECT trial, which analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer.

Dr. Cohen on the Rationale of the Active8 Study in SCCHN

July 10th 2014

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the rationale of the Active8 study.

Importance of Multidisciplinary Thyroid Cancer Care

July 9th 2014

Treatment Selection in Advanced MTC

July 9th 2014

Utilizing TKIs in Advanced Medullary Thyroid Cancer

July 9th 2014

Diagnosis and Initial Treatment of MTC

July 9th 2014

Managing Sorafenib-Related AEs in Thyroid Cancer

July 9th 2014

Case Study: Treating Papillary Thyroid Cancer

July 9th 2014

Role of the Endocrinologist in RAI-Refractory Thyroid Cancer

July 9th 2014